Literature DB >> 11937356

Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives.

Seiichiro Ogawa1, Yuko Kobayashi Matsunaga, Yoshiyuki Suzuki.   

Abstract

N-Octyl-beta-valienemine (1), a potent beta-glucocerebrosidase inhibitor, was chemically transformed into two biologically interesting compounds: the 4-epimer, beta-galacto-type N-octyl-valienamine, and the 4-O-(beta-D-galactopyranosyl) derivative, a carba-lactosylceramide analogue. The former, interestingly, could be demonstrated to act as a very effective inhibitor (IC(50)=0.3 microM) of human beta-galactosidase. The latter exhibited moderate inhibitory activity (IC(50)=20 microM) against beta-glucocerebrosidase (mouse liver).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937356     DOI: 10.1016/s0968-0896(02)00005-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.

Authors:  Mohammad Arif Hossain; Katsumi Higaki; Seiji Saito; Kazuki Ohno; Hitoshi Sakuraba; Eiji Nanba; Yoshiyuki Suzuki; Keiichi Ozono; Norio Sakai
Journal:  J Hum Genet       Date:  2015-06-25       Impact factor: 3.172

2.  Beta-galactosidase deficiency: an approach to chaperone therapy.

Authors:  Yoshiyuki Suzuki
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

3.  Synthesis of a New β-Galactosidase Inhibitor Displaying Pharmacological Chaperone Properties for GM1 Gangliosidosis.

Authors:  Francesca Clemente; Macarena Martínez-Bailén; Camilla Matassini; Amelia Morrone; Silvia Falliano; Anna Caciotti; Paolo Paoli; Andrea Goti; Francesca Cardona
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

4.  Novel stereoselective syntheses of N-octyl-β-valienamine (NOV) and N-octyl-4-epi-β-valienamine (NOEV) from (-)-shikimic acid.

Authors:  Feng-Lei Li; Jiang-Ping Yu; Wei Ding; Mian-Mian Sun; Yun-Gang He; Xing-Liang Zhu; Shi-Ling Liu; Xiao-Xin Shi
Journal:  RSC Adv       Date:  2019-12-18       Impact factor: 4.036

5.  A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.

Authors:  Tomoko Takai; Katsumi Higaki; Matilde Aguilar-Moncayo; Teresa Mena-Barragán; Yuki Hirano; Kei Yura; Liang Yu; Haruaki Ninomiya; M Isabel García-Moreno; Yasubumi Sakakibara; Kousaku Ohno; Eiji Nanba; Carmen Ortiz Mellet; José M García Fernández; Yoshiyuki Suzuki
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

6.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

7.  Structural basis of pharmacological chaperoning for human β-galactosidase.

Authors:  Hironori Suzuki; Umeharu Ohto; Katsumi Higaki; Teresa Mena-Barragán; Matilde Aguilar-Moncayo; Carmen Ortiz Mellet; Eiji Nanba; Jose M Garcia Fernandez; Yoshiyuki Suzuki; Toshiyuki Shimizu
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

Review 8.  Design and synthesis of biologically active carbaglycosylamines: From glycosidase inhibitors to pharmacological chaperones.

Authors:  Seiichiro Ogawa; Shinichi Kuno; Tatsushi Toyokuni
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2022       Impact factor: 3.945

9.  Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.

Authors:  Yoshiyuki Suzuki; Seiichiro Ogawa; Yasubumi Sakakibara
Journal:  Perspect Medicin Chem       Date:  2009-05-26

Review 10.  Emerging novel concept of chaperone therapies for protein misfolding diseases.

Authors:  Yoshiyuki Suzuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2014       Impact factor: 3.493

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.